Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen ...

We read with great interest the published results of the RADIOSA trial by Giulia Marvaso and colleagues.1 This well designed ...

To close out Men’s Health Month, the Cancer Connections team sat down with Dr. William Dahut, the American Cancer Society’s ...

A highly expensive, revolutionary treatment for recurrent prostate cancer is for the first time in Australia available at a ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a Radiopharmaceutical Therapy Trials with Dosimetry session. Dr.

Although acute toxicity was higher for ultra-hypofractionation than conventional fractionation, this long-term patient-reported QOL analysis shows that ultra-hypofractionation was as well tolerated as ...

Mogensen AW et al. The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer ...

In fact, one in eight men will be diagnosed with prostate cancer during their lifetime, according to the American Cancer Society. Advancements in medicine, however, are helping to personalize ...

Salvage radiotherapy (RT), delivered over ≥4 wk, is a current standard of care. A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks ...

In recent years, there has been a headlong rush into the use of prostate-specific membrane antigen (PSMA)–targeted PET for ...

International guidelines recommend salvage radiotherapy (sRT) as a curative treatment for men with biochemically recurrent prostate cancer after radical prostatectomy. Prostate-specific membrane ...

So, even if imaging is negative but the PSA is detectable and risk factors are present, salvage radiation therapy should still be offered. ... New AUA/ASTRO/SUO prostate cancer salvage therapy ...